Return to Today's science sparks archives

2019-10-01

Fig 1. A Pictorial Timeline of the Discovery of Herceptin.

Fig 1. A Pictorial Timeline of the Discovery of Herceptin.
  • Sawyers CL

  • Cell. 2019 Sep 19;179(1):8-12.

2019-10-02

Fig. 1. Patient-reported outcomes.

Fig. 1. Patient-reported outcomes.
  • Zhi WI, Chen P, Kwon A, Chen C, Harte SE, Piulson L, Li S, Patil S, Mao JJ, Bao T

  • Breast Cancer Res Treat. 2019 Aug 27.

2019-10-03

Figure 1. TBR2 removal causes a reduction in excitatory neuronal output of individual RGPs.

Figure 1. TBR2 removal causes a reduction in excitatory neuronal output of individual RGPs.
  • Lv X, Ren SQ, Zhang XJ, Shen Z, Ghosh T, Xianyu A, Gao P, Li Z, Lin S, Yu Y, Zhang Q, Groszer M, Shi SH

  • Nat Commun. 2019 Sep 2;10(1):3946.
Open Access button

2019-10-04

Fig 2. Genomic correlates of contrast-enhancement on brain imaging in IDH-mutant tumors.

Fig 2. Genomic correlates of contrast-enhancement on brain imaging in IDH-mutant tumors.
  • Jonsson P, Lin AL, Young RJ, DiStefano NM, Hyman DM, Li BT, Berger MF, Zehir A, Ladanyi M, Solit DB, Arnold AG, Stadler ZK, Mandelker D, Goldberg ME, Chmielecki J, Pourmaleki M, Ogilvie SQ, Chavan SS, McKeown AT, Manne M, Hyde A, Beal K, Yang TJ, Nolan CP, Pentsova E, Omuro A, Gavrilovic IT, Kaley TJ, Diamond EL, Stone JB, Grommes C, Boire A, Daras M, Piotrowski AF, Miller AM, Gutin PH, Chan TA, Tabar VS, Brennan CW, Rosenblum M, DeAngelis LM, Mellinghoff IK, Taylor BS

  • Clin Cancer Res. 2019 Sep 15;25(18):5537-5547.
Open Access button

2019-10-07

Fig. 2 Scalp cooling workflow.

Fig. 2 Scalp cooling workflow.
  • Fischer-Cartlidge E, Ross M, Hernández K, Featherstone A, Haase C

  • Clin J Oncol Nurs. 2018 Oct 1;22(5):534-541.

2019-10-08

Fig. 1. DCE perfusion MR imaging in a 55-year-old woman with brain metastasis. T1-weighted, Ktrans, and Vp images are shown at multiple time points.

Fig. 1. DCE perfusion MR imaging in a 55-year-old woman with brain metastasis. T1-weighted, Ktrans, and Vp images are shown at multiple time points.
  • Gharzeddine K, Hatzoglou V, Holodny AI, Young RJ

  • Radiol Clin North Am. 2019 Nov;57(6):1177-1188.

2019-10-09

FIG 2. Bone marrow biopsy showed extensive fibrosis and very little remaining hematopoietic elements.

FIG 2. Bone marrow biopsy showed extensive fibrosis and very little remaining hematopoietic elements.
  • Stanchina M, Rosenbaum E, Pronko AJ, Liu Y, Lewis N, Yabe M, Stein E, Taylor J

  • J Oncol Pract. 2019 Aug;15(8):458-459.

2019-10-10

Fig 2.  (a) Kaplan–Meier curves of the eight TCGA BRCA subtypes identified by the ab-SNF method with the number of subjects in each subtypes.

Fig 2. (a) Kaplan–Meier curves of the eight TCGA BRCA subtypes identified by the ab-SNF method with the number of subjects in each subtypes.
  • Ruan P, Wang Y, Shen R, Wang S

  • Bioinformatics. 2019 Oct 1;35(19):3718-3726.
Open Access button

2019-10-11

Fig 1. Approach to Choosing Systematic Therapy for Patients With Metastatic Non–Small Cell Lung Cancer.

Fig 1. Approach to Choosing Systematic Therapy for Patients With Metastatic Non–Small Cell Lung Cancer.
  • Arbour KC, Riely GJ

  • JAMA. 2019 Aug 27;322(8):764-774.

2019-10-14

Figure 1. Reported awareness and satisfaction with MSK Cancer Alliance activities.

Figure 1. Reported awareness and satisfaction with MSK Cancer Alliance activities.
  • Lipitz-Snyderman A, Kennington J, Hogan B, Korenstein D, Kalman L, Nair S, Yu P, Sabbatini P, Pfister D

  • J Natl Compr Canc Netw. 2019 Sep 1;17(9):1083-1087.
Open Access button

2019-10-15

Figure 1. T cells embed into micropillar arrays.

Figure 1. T cells embed into micropillar arrays.
  • Jin W, Tamzalit F, Chaudhuri PK, Black CT, Huse M, Kam LC

  • Proc Natl Acad Sci U S A. 2019 Oct 1;116(40):19835-19840.
Open Access button

2019-10-16

Figure 3. A 69-y-old patient with history of Gleason 7 PCa treated with high-intensity focus ultrasound therapy 1 year previously.

Figure 3. A 69-y-old patient with history of Gleason 7 PCa treated with high-intensity focus ultrasound therapy 1 year previously.
  • Ghafoor S, Burger IA, Vargas AH

  • J Nucl Med. 2019 Oct;60(10):1350-1358.
Open Access button

2019-10-17

Figure 2. Summary of HR processes and HR proteins reported for sumoylation and interacting with SUMO.

Figure 2. Summary of HR processes and HR proteins reported for sumoylation and interacting with SUMO.
  • Dhingra N, Zhao X

  • Genes Dev. 2019 Oct 1;33(19-20):1346-1354.
Open Access button

2019-10-18

Figure 1. Frequency of brain metastases found at diagnosis and developing on treatment in patients with HER2‐, KRAS‐, and EGFR‐mutant lung cancers.

Figure 1. Frequency of brain metastases found at diagnosis and developing on treatment in patients with HER2‐, KRAS‐, and EGFR‐mutant lung cancers.
  • Offin M, Feldman D, Ni A, Myers ML, Lai WV, Pentsova E, Boire A, Daras M, Jordan EJ, Solit DB, Arcila ME, Jones DR, Isbell JM, Beal K, Young RJ, Rudin CM, Riely GJ, Drilon A, Tabar V, DeAngelis LM, Yu HA, Kris MG, Li BT

  • Cancer. 2019 Aug 30.

2019-10-21

Fig 1. Study conceptual model. ACCESS, ambulatory cancer care electronic symptom self-reporting; ED, emergency department; MSK, Memorial Sloan Kettering Cancer Center.

Fig 1. Study conceptual model. ACCESS, ambulatory cancer care electronic symptom self-reporting; ED, emergency department; MSK, Memorial Sloan Kettering Cancer Center.
  • Stabile C, Temple LK, Ancker JS, Basch E, Carter J, Miranda M, Stein D, Stetson PD, Vickers A, Simon BA, Pusic AL

  • BMJ Open. 2019 Sep 17;9(9):e030863.
Open Access button

2019-10-22

Fig 2. Identification of AGX51.

Fig 2. Identification of AGX51.
  • Wojnarowicz PM, Lima E Silva R, Ohnaka M, Lee SB, Chin Y, Kulukian A, Chang SH, Desai B, Garcia Escolano M, Shah R, Garcia-Cao M, Xu S, Kadam R, Goldgur Y, Miller MA, Ouerfelli O, Yang G, Arakawa T, Albanese SK, Garland WA, Stoller G, Chaudhary J, Norton L, Soni RK, Philip J, Hendrickson RC, Iavarone A, Dannenberg AJ, Chodera JD, Pavletich N, Lasorella A, Campochiaro PA, Benezra R

  • Cell Rep. 2019 Oct 1;29(1):62-75.e7.
Open Access button

2019-10-23

Fig 1. Median PFS with first-line EGFR-TKI treatment in EGFR mutation-positive NSCLC and the proportion of patients who received subsequent systemic treatment

Fig 1. Median PFS with first-line EGFR-TKI treatment in EGFR mutation-positive NSCLC and the proportion of patients who received subsequent systemic treatment
  • Gelatti ACZ, Drilon A, Santini FC

  • Lung Cancer. 2019 Sep 23;137:113-122.
Open Access button

2019-10-24

Fig. 1. DNA demethylation agent 5-Aza-dC inhibits ALVJ replication in vitro.

Fig. 1. DNA demethylation agent 5-Aza-dC inhibits ALVJ replication in vitro.
  • Chen S, Hu X, Cui IH, Wu S, Dou C, Liu Y, Sun Z, Xue S, Geng T, Liu Z, Qin A, Cui H

  • Antiviral Res. 2019 Oct;170:104571.
Open Access button

2019-10-25

Figure 1. TRIM33 and Smad2/3 Colocalize at Chromatin of Mesendodermal Genes in EBs, but Not in ESCs.

Figure 1. TRIM33 and Smad2/3 Colocalize at Chromatin of Mesendodermal Genes in EBs, but Not in ESCs.
  • Luo M, Bai J, Liu B, Yan P, Zuo F, Sun H, Sun Y, Xu X, Song Z, Yang Y, Massagué J, Lan X, Lu Z, Chen YG, Deng H, Xie W, Xi Q

  • Stem Cell Reports. 2019 Sep 16. pii: S2213-6711(19)30310-8.
Open Access button

2019-10-28

Fig. 1. Overview of CellAssign.

Fig. 1. Overview of CellAssign.
  • Zhang AW, O'Flanagan C, Chavez EA, Lim JLP, Ceglia N, McPherson A, Wiens M, Walters P, Chan T, Hewitson B, Lai D, Mottok A, Sarkozy C, Chong L, Aoki T, Wang X, Weng AP, McAlpine JN, Aparicio S, Steidl C, Campbell KR, Shah SP

  • Nat Methods. 2019 Oct;16(10):1007-1015.

2019-10-29

Figure 1. General neddylation cascade.

Figure 1. General neddylation cascade.
  • Kim HS, Hammill JT, Scott DC, Chen Y, Min J, Rector J, Singh B, Schulman BA, Guy RK

  • J Med Chem. 2019 Sep 26;62(18):8429-8442.

2019-10-30

Fig 1. History of the molecular classification of breast cancer. Names are shown at the chronological level at which they were introduced.

Fig 1. History of the molecular classification of breast cancer. Names are shown at the chronological level at which they were introduced.
  • Mathews JC, Nadeem S, Levine AJ, Pouryahya M, Deasy JO, Tannenbaum A

  • NPJ Breast Cancer. 2019 Sep 9;5:30. doi: 10.1038/s41523-019-0124-8. eCollection 2019.
Open Access button

2019-10-31

Fig 1. Percent signal change data for the moving and static stimuli from all five categories (faces, bodies, scenes, objects and scrambled objects) in face-selective ROIs. The rpSTS and raSTS, ROIs on the lateral surface showed a significantly greater response to moving faces than to static faces (*denotes significant effects in Bonferroni corrected tests p < 0.001).

Fig 1. Percent signal change data for the moving and static stimuli from all five categories (faces, bodies, scenes, objects and scrambled objects) in face-selective ROIs. The rpSTS and raSTS, ROIs on the lateral surface showed a significantly greater response to moving faces than to static faces (*denotes significant effects in Bonferroni corrected tests p < 0.001).
  • Pitcher D, Ianni G, Ungerleider LG

  • Sci Rep. 2019 Jun 3;9(1):8242.
Open Access button

2019-11-01

Fig 1. Clinical nurse specialist portfolio example.

Fig 1. Clinical nurse specialist portfolio example.
  • Fischer-Cartlidge E, Houlihan N, Browne K

  • Clin Nurse Spec. 2019 Nov/Dec;33(6):266-272.

2019-11-04

Fig. AR expression in salivary duct carcinoma (SDC).

Fig. AR expression in salivary duct carcinoma (SDC).
  • Xu B, Dogan S, Haroon A, Rasheed MR, Ghossein R, Katabi N

  • Hum Pathol. 2019 Aug 17;93:30-36.

2019-11-05

Fig 2. Transcriptomic landscape of live, dead, and dying cells

Fig 2. Transcriptomic landscape of live, dead, and dying cells
  • O'Flanagan CH, Campbell KR, Zhang AW, Kabeer F, Lim JLP, Biele J, Eirew P, Lai D, McPherson A, Kong E, Bates C, Borkowski K, Wiens M, Hewitson B, Hopkins J, Pham J, Ceglia N, Moore R, Mungall AJ, McAlpine JN; CRUK IMAXT Grand Challenge Team, Shah SP, Aparicio S

  • Genome Biol. 2019 Oct 17;20(1):210.
Open Access button

2019-11-06

Fig 2. MYB-NFIB fusion transcripts and gene expression pattern in ACC PDXs and ACC cell line.

Fig 2. MYB-NFIB fusion transcripts and gene expression pattern in ACC PDXs and ACC cell line.
  • Jiang Y, Gao R, Cao C, Forbes L, Li J, Freeberg S, Fredenburg KM, Justice JM, Silver NL, Wu L, Varma S, West R, Licht JD, Zajac-Kaye M, Kentsis A, Kaye FJ

  • Oral Oncol. 2019 Oct 10;98:147-155.

2019-11-08

Fig 3. Analyses of the Treatment-free Interval and Outcomes after Treatment

Fig 3. Analyses of the Treatment-free Interval and Outcomes after Treatment
  • Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD

  • N Engl J Med. 2019 Oct 17;381(16):1535-1546.

2019-11-11

Fig 2. Example of diagnostic interpretation error in false-negative sentinel lymph node.

Fig 2. Example of diagnostic interpretation error in false-negative sentinel lymph node.
  • Grabenstetter A, Moo TA, Hajiyeva S, Schüffler PJ, Khattar P, Friedlander MA, McCormack MA, Raiss M, Zabor EC, Barrio A, Morrow M, Edelweiss M

  • Am J Surg Pathol. 2019 Oct;43(10):1377-1383.

2019-11-12

Fig. 3: Experimental imaging results.

Fig. 3: Experimental imaging results.
  • Liu T, Rajadhyaksha M, Dickensheets DL

  • Light Sci Appl. 2019 Jun 26;8:59.
Open Access button

2019-11-13

Figure 1. Macrophages of distinct developmental origin coexist in the adipose tissue of lean and obese animals.

Figure 1. Macrophages of distinct developmental origin coexist in the adipose tissue of lean and obese animals.
  • Cox N, Geissmann F

  • Curr Opin Immunol. 2019 Oct 25;62:1-8.

2019-11-14

Figure 2. Functional consequences of SF3B1, SRSF2, and U2AF1 mutations in on RNA splicing.

Figure 2. Functional consequences of SF3B1, SRSF2, and U2AF1 mutations in on RNA splicing.
  • Taylor J, Lee SC

  • Genes Chromosomes Cancer. 2019 Dec;58(12):889-902.
Open Access button

2019-11-15

Fig 1. Estrogen synthesis and metabolism

Fig 1. Estrogen synthesis and metabolism
  • Romero SAD, Su HI, Satagopan J, Li QS, Seluzicki CM, Dries A, DeMichele AM, Mao JJ

  • Breast. 2019 Oct 22;49:48-54.
Open Access button

2019-11-18

Fig 6. Clinical and in vitro validation of MITF in basal breast cancer.

Fig 6. Clinical and in vitro validation of MITF in basal breast cancer.
  • Osmanbeyoglu HU, Shimizu F, Rynne-Vidal A, Alonso-Curbelo D, Chen HA, Wen HY, Yeung TL, Jelinic P, Razavi P, Lowe SW, Mok SC, Chiosis G, Levine DA, Leslie CS

  • Nat Commun. 2019 Sep 25;10(1):4369.
Open Access button

2019-11-20

Illustration of the effects of psychological factors and prognosis on the relative proportions of patients with accurate and inaccurate understanding of recently discussed scan results, as indicated by concordance with their clinician's rating.

Illustration of the effects of psychological factors and prognosis on the relative proportions of patients with accurate and inaccurate understanding of recently discussed scan results, as indicated by concordance with their clinician's rating.
  • Derry HM, Maciejewski PK, Epstein AS, Shah MA, LeBlanc TW, Reyna V, Prigerson HG

  • J Palliat Med. 2019 Aug;22(8):961-965.

2019-11-21

Fig 1. BRD9 mis-splicing causes BRD9 loss and proliferative advantage in SF3B1-mutated cancers; c. CRISPR–Cas9-based positive-selection screen targeting genes for which mutant SF3B1 promotes an isoform predicted to trigger NMD.

Fig 1. BRD9 mis-splicing causes BRD9 loss and proliferative advantage in SF3B1-mutated cancers; c. CRISPR–Cas9-based positive-selection screen targeting genes for which mutant SF3B1 promotes an isoform predicted to trigger NMD.
  • Inoue D, Chew GL, Liu B, Michel BC, Pangallo J, D'Avino AR, Hitchman T, North K, Lee SC, Bitner L, Block A, Moore AR, Yoshimi A, Escobar-Hoyos L, Cho H, Penson A, Lu SX, Taylor J, Chen Y, Kadoch C, Abdel-Wahab O, Bradley RK

  • Nature. 2019 Oct 9.

2019-11-22

Fig 5. Unique features of Il2-expressing CD4SP thymocytes inferred from scRNA transcriptomics.

Fig 5. Unique features of Il2-expressing CD4SP thymocytes inferred from scRNA transcriptomics.
  • Hemmers S, Schizas M, Azizi E, Dikiy S, Zhong Y, Feng Y, Altan-Bonnet G, Rudensky AY

  • J Exp Med. 2019 Nov 4;216(11):2466-2478.

2019-11-25

Fig. 2 Effect sizes for changes on cognitive measures.

Fig. 2 Effect sizes for changes on cognitive measures.
  • Janelsins MC, Heckler CE, Peppone LJ, Ahles TA, Mohile SG, Mustian KM, Palesh O, O'Mara AM, Minasian LM, Williams AM, Magnuson A, Geer J, Dakhil SR, Hopkins JO, Morrow GR

  • J Clin Oncol. 2018 Sep 21:JCO2018786624.

2019-11-26

Fig 4. 3D reconstruction of the CT scan of the mandible showing only slight expansion of the lateral cortex of the madible (A), and axial view of the CT scan in bone window majority of the tumor being endosteal with a slight expansion of the lateral cortex (B).

Fig 4. 3D reconstruction of the CT scan of the mandible showing only slight expansion of the lateral cortex of the madible (A), and axial view of the CT scan in bone window majority of the tumor being endosteal with a slight expansion of the lateral cortex (B).
  • Petrovic I, Ahmed ZU, Hay A, Rosen EB, Lu C, Hameed M, Shah JP

  • J Surg Oncol. 2019 Aug;120(2):109-116.

2019-11-27

Figure 5. Radar charts displaying the number of mentions for preferred.

Figure 5. Radar charts displaying the number of mentions for preferred.
  • Bickel H, Polanec SH, Wengert G, Pinker K, Bogner W, Helbich TH, Baltzer PA

  • J Magn Reson Imaging. 2019 Dec;50(6):1754-1761.

2019-11-29

Fig. 1 Rate of CPM in women with T4M0 breast cancer stratified by clinical AJCC T4 subtypes T4abc, T4d, and NOS.

Fig. 1 Rate of CPM in women with T4M0 breast cancer stratified by clinical AJCC T4 subtypes T4abc, T4d, and NOS.
  • Panchal H, Pilewskie ML, Sheckter CC, Albornoz CR, Razdan SN, Disa JJ, Cordeiro PG, Mehrara BJ, Matros E

  • J Surg Oncol. 2019 Jan;119(1):79-87.

2019-12-02

FIG 1. (A) Best change from baseline in target lesion by best overall response per investigator.

FIG 1. (A) Best change from baseline in target lesion by best overall response per investigator.
  • Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz AJ

  • J Clin Oncol. 2019 Nov 20;37(33):3081-3089.

2019-12-03

Fig 1. Multiple Hit-Induced Multisystem Toxicity in Astronauts and Cancer Patients.

Fig 1. Multiple Hit-Induced Multisystem Toxicity in Astronauts and Cancer Patients.
  • Scott JM, Dolan LB, Norton L, Charles JB, Jones LW

  • Cell. 2019 Nov 14;179(5):1003-1009.

2019-12-04

Fig. 3. a) Serial PET imaging of the same animal bearing single orthotopic 4T1 mammary fat pad allograft after intravenous administration of 3.7 MBq (60 μg) of [89Zr]Zr-DFO-CNC-Cy5 shows accumulation of the nanocrystals in the liver, spleen, and bone.

Fig. 3. a) Serial PET imaging of the same animal bearing single orthotopic 4T1 mammary fat pad allograft after intravenous administration of 3.7 MBq (60 μg) of [89Zr]Zr-DFO-CNC-Cy5 shows accumulation of the nanocrystals in the liver, spleen, and bone.
  • Sarparanta M, Pourat J, Carnazza KE, Tang J, Paknejad N, Reiner T, Kostiainen MA, Lewis JS

  • Nucl Med Biol. 2019 Nov 9;80-81:1-12.

2019-12-05

Figure 2. DNA Methylation across six IDH1/2 mutant cancers.

Figure 2. DNA Methylation across six IDH1/2 mutant cancers.
  • Bledea R, Vasudevaraja V, Patel S, Stafford J, Serrano J, Esposito G, Tredwin LM, Goodman N, Kloetgen A, Golfinos JG, Zagzag D, Weigelt B, Iafrate AJ, Sulman EP, Chi AS, Dogan S, Reis-Filho JS, Chiang S, Placantonakis D, Tsirigos A, Snuderl M

  • Sci Rep. 2019 Nov 14;9(1):16830.
Open Access button

2019-12-09

Fig 1. Discovery and validation of the molecular profile of patients with resected early gastric cancer and unexpectedly poor survival.

Fig 1. Discovery and validation of the molecular profile of patients with resected early gastric cancer and unexpectedly poor survival.
  • Datta J, Da Silva EM, Kandoth C, Song T, Russo AE, Hernandez JM, Taylor BS, Janjigian YY, Tang LH, Solit DB, Strong VE

  • Br J Surg. 2019 Nov 25.
Open Access button

2019-12-10

Fig. 3 Estimated marginal probability and corresponding 95% CIs of the receipt of genetic testing across different surgeons.

Fig. 3 Estimated marginal probability and corresponding 95% CIs of the receipt of genetic testing across different surgeons.
  • Katz SJ, Bondarenko I, Ward KC, Hamilton AS, Morrow M, Kurian AW, Hofer TP

  • JAMA Surg. 2018 Oct 1;153(10):909-916.

2019-12-11

Figure 3. Spatial heterogeneity of somatic mutations across tumor regions.

Figure 3. Spatial heterogeneity of somatic mutations across tumor regions.
  • Niknafs N, Zhong Y, Moral JA, Zhang L, Shao MX, Lo A, Makohon-Moore A, Iacobuzio-Donahue CA, Karchin R

  • Nat Commun. 2019 Nov 28;10(1):5435.
Open Access button

2019-12-12

Fig 1. Sequential therapy. Durable responses to first-generation TRK inhibitors can be achieved in TRK fusion-positive cancers.

Fig 1. Sequential therapy. Durable responses to first-generation TRK inhibitors can be achieved in TRK fusion-positive cancers.
  • Drilon A

  • Ann Oncol. 2019 Nov 1;30(Supplement_8):viii23-viii30.
Open Access button

2019-12-13

Fig 1. Factors precluding the initiation of durvalumab after chemoradiation in stage III NSCLC were identified among the 26 patients (27%) in whom durvalumab consolidation was forgone.

Fig 1. Factors precluding the initiation of durvalumab after chemoradiation in stage III NSCLC were identified among the 26 patients (27%) in whom durvalumab consolidation was forgone.
  • Shaverdian N, Offin MD, Rimner A, Shepherd AF, Wu AJ, Rudin CM, Hellmann MD, Chaft JE, Gomez DR

  • Radiother Oncol. 2019 Nov 28;144:101-104.

2019-12-16

Fig 1. HPV-associated head and neck cancers are associated with increased utilization of microhomology at deletion breakpoints without signatures of homologous recombination deficiency.

Fig 1. HPV-associated head and neck cancers are associated with increased utilization of microhomology at deletion breakpoints without signatures of homologous recombination deficiency.
  • Leeman JE, Li Y, Bell A, Hussain SS, Majumdar R, Rong-Mullins X, Blecua P, Damerla R, Narang H, Ravindran PT, Lee NY, Riaz N, Powell SN, Higginson DS

  • Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21573-21579.

2019-12-17

Fig 1. Step by step imaging approaches for optimal management of unresectable P-NETs.

Fig 1. Step by step imaging approaches for optimal management of unresectable P-NETs.
  • Rozenblum L, Mokrane FZ, Yeh R, Sinigaglia M, Besson FL, Seban RD, Zadro C, Dierickx L, Chougnet CN, Partouche E, Revel-Mouroz P, Zhao B, Otal P, Schwartz LH, Dercle L

  • Eur J Radiol. 2019 Nov 12;122:108743.

2019-12-18

Figure 3. Histological validation of Hsp1a-FL.

Figure 3. Histological validation of Hsp1a-FL.
  • Gonzales J, Demetrio de Souza Franca P, Jiang Y, Pirovano G, Kossatz S, Guru N, Yarilin D, Agwa AJ, Schroeder CI, Patel SG, Ganly I, King GF, Reiner T.

  • Bioconjug Chem. 2019 Nov 20;30(11):2879-2888.

2019-12-19

Fig. 1: Identification of PPARɣ-repressed transcription factors.

Fig. 1: Identification of PPARɣ-repressed transcription factors.
  • Yamashita H, Kawasawa YI, Shuman L, Zheng Z, Tran T, Walter V, Warrick JI, Chen G, Al-Ahmadie H, Kaag M, Wong PK, Raman JD, DeGraff DJ

  • Oncogenesis. 2019 Nov 26;8(12):69.
Open Access button

2019-12-20

Figure 1. Digital pathology suite.

Figure 1. Digital pathology suite.
  • Hanna MG, Reuter VE, Samboy J, England C, Corsale L, Fine SW, Agaram NP, Stamelos E, Yagi Y, Hameed M, Klimstra DS, Sirintrapun SJ

  • Arch Pathol Lab Med. 2019 Dec;143(12):1545-1555.
Open Access button

2019-12-23

Fig 1. The TCGA and MSK-IMPACT data.

Fig 1. The TCGA and MSK-IMPACT data.
  • Chakraborty S, Arora A, Begg CB, Shen R

  • Nat Commun. 2019 Dec 3;10(1):5506.
Open Access button

2019-12-24

Figure 4. Fluorescence in situ hybridization in the index case revealed the presence of aPLAG1 break-apart signal, in keeping with a gene rearrangement (red, centromeric; green, telomeric).

Figure 4. Fluorescence in situ hybridization in the index case revealed the presence of aPLAG1 break-apart signal, in keeping with a gene rearrangement (red, centromeric; green, telomeric).
  • Yuan L, Katabi N, Antonescu CR, Golden A, Travis WD, Rekhtman N

  • Am J Surg Pathol. 2020 Jan;44(1):140-147.

2019-12-26

Figure 1. Rif2 inhibits MRX-dependent activation of Tel1 kinase.

Figure 1. Rif2 inhibits MRX-dependent activation of Tel1 kinase.
  • Hailemariam S, De Bona P, Galletto R, Hohl M, Petrini JH, Burgers PM

  • J Biol Chem. 2019 Dec 6;294(49):18846-18852.

2019-12-27

Fig. 3 Metagenomic and metabolomic analyses of Enterococcus-dominated fecal specimens in human HCT patients and mice.

Fig. 3 Metagenomic and metabolomic analyses of Enterococcus-dominated fecal specimens in human HCT patients and mice.
  • Stein-Thoeringer CK, Nichols KB, Lazrak A, Docampo MD, Slingerland AE, Slingerland JB, Clurman AG, Armijo G, Gomes ALC, Shono Y, Staffas A, Burgos da Silva M, Devlin SM, Markey KA, Bajic D, Pinedo R, Tsakmaklis A, Littmann ER, Pastore A, Taur Y, Monette S, Arcila ME, Pickard AJ, Maloy M, Wright RJ, Amoretti LA, Fontana E, Pham D, Jamal MA, Weber D, Sung AD, Hashimoto D, Scheid C, Xavier JB, Messina JA, Romero K, Lew M, Bush A, Bohannon L, Hayasaka K, Hasegawa Y, Vehreschild MJGT, Cross JR, Ponce DM, Perales MA, Giralt SA, Jenq RR, Teshima T, Holler E, Chao NJ, Pamer EG, Peled JU, van den Brink MRM

  • Science. 2019 Nov 29;366(6469):1143-1149.

2019-12-30

Figure 1. Structure of Candida Trl1 KIN-CPD.

Figure 1. Structure of Candida Trl1 KIN-CPD.
  • Banerjee A, Goldgur Y, Schwer B, Shuman S

  • Nucleic Acids Res. 2019 Dec 16;47(22):11826-11838.